

CMP: ₹ 1640

Target: ₹ 1925(17%)

Target Period: 12 months

BUY

May 23, 2025

## Cautious guidance but momentum from margin accretive themes intact ...

**About the stock:** Sun is the world's fourth largest generics/specialty pharma company with 43 manufacturing sites at its disposal addressing segments like specialty products, branded generics, complex generics, pure generics and APIs.

- Sun is ranked No. 1 in domestic formulations. It enjoys a leadership position in 12 specialties based on prescription.
- Revenue break-up Q4FY25: US formulations~31%, Indian branded~33%, Emerging markets~17%, RoW~13%, API & Others ~5%
- The company is consciously ramping up its global specialty portfolio (Innovative products) which now accounts for ~20% of sales (spread across geographies but mainly US)

### Investment Rationale:

- **Q4FY25- Strong numbers despite flat US growth** Revenues grew ~8% YoY to ₹ 12959 crore driven mainly by strong growth in India, specialty drugs and emerging markets. India growth was strong at 13.5% to ₹ 4213 crore. The US remained subdued with a growth of 1.7% to ₹ 4020 crore due to weakness in generics despite decent Specialty traction. Emerging markets grew ~11% to ₹ 2256 crore. RoW markets reported growth of ~6% to ₹ 1734 crore, mainly due to milestone income and volume expansion. Global Specialty sales came in at US\$ 295 million, a growth at ~9%. EBITDA stood at ₹ 3425 crore, up ~11% YoY, with resulting EBITDA margins of 26.4%, GPM dipped by ~49 bps to 79.6%. Net profit came in at ₹ 1859 crore, down 31.4% YoY.
- **Domestic Formulations, Global Specialty to remain money-spinners-** The India business continued to deliver volume-driven growth. Specialty sales were a little subdued compared to lower offtake in January and February but as per management the Rx and Inventory trend still looks promising. Besides R&D spend guidance of 6-8% of sales (1/3rd for Specialty) the management has indicated another US\$ 100 million for Specialty (additional SG&A). However, FY26 revenue growth guidance of mid to high single digit growth looks conservative given the potential of the Specialty pipeline and the expected traction in India business. The management has sighted global uncertainty and currency volatility as main reasons for a conservative guidance. That said, we expect better profitability as the growth would be driven by remunerative businesses, The company is sitting on a cash pile of US\$3 billion, which gives ample scope for the company to look out for high value assets even at tad higher valuation.

### Rating and Target price

- We maintain BUY with a target price of ₹ 1925 based on 36x FY27E EPS of ₹53.5. Premium valuation is justified on account of strong FCF generation driven by focus on margin accretive businesses.




#### Particulars

Particular	Amount
Market Capitalisation	₹ 393436 Crore
Debt (FY25)	₹ 2360 Crore
Cash & Equivalents (FY25)	₹ 10269 Crore
EV	₹ 385527 Crore
52 week H/L (₹)	1960/1377
Equity capital	₹ 240 Crore
Face value	₹ 1

#### Shareholding pattern

(in %)	Jun-24	Sep-24	Dec-24	Mar-25
Promoter	54.5	54.5	54.5	54.5
FII	17.2	18.0	18.0	18.0
DII	19.2	18.5	18.4	18.6
Others	9.1	9.0	9.1	9.0

#### Price Chart



#### Key risks

- Slower ramp-up in the Specialty launches due to longer than expected gestation period
- Delay in generic ramp-up due to pending Halol and Dadra USFDA embargo

#### Research Analyst

Siddhant Khandekar  
siddhant.khandekar@icicisecurities.com

Shubh Mehta  
shubh.mehta@icicisecurities.com

Vedant Nilekar  
vedant.nilekar@icicisecurities.com

#### Key Financial Summary

Key Financials (₹ Crore)	FY22	FY23	FY24	2 year CAGR (FY22-24)	FY25	FY26E	FY27E	2 year CAGR (FY25E-27E)
Net Sales	38654.5	43885.5	48496.9	12.0	52578.4	56864.8	62059.5	8.6
EBITDA	10397.7	11673.8	12987.0	11.8	15086.2	15922.1	17376.7	7.3
EBITDA Margins (%)	26.9	26.6	26.8		28.7	28.0	28.0	
Adj. Profit	7667.1	8655.2	9994.4	14.2	11443.2	11904.7	12822.8	5.9
Adj. EPS (₹)	32.0	36.1	41.7		47.7	49.6	53.5	
PE (x)	120.2	46.3	41.2		36.6	33.0	30.7	
EV to EBITDA (x)	36.7	33.1	29.2		24.6	23.0	20.7	
RoE (%)	16.0	15.5	15.7		15.8	14.7	14.2	
RoCE (%)	18.2	15.3	17.5		20.2	18.8	18.6	

Source: Company, ICICI Direct Research



## Exhibit 1: Quarterly Summary

(₹ Crore)	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	YoY (%)	QoQ (%)
Total Operating Income	9446.8	10761.8	10952.3	11240.8	10930.7	11940.8	12192.4	12380.7	11982.9	12652.8	13291.4	13675.5	12958.8	8.1	-5.2
Raw Material Expenses	2539.6	2900.2	2708.1	2803.7	2250.2	2758.2	2787.1	2736.9	2380.4	2675.4	2694.2	2740.5	2637.2	10.8	-3.8
Gross Profit Margin (%)	73.1	73.1	75.3	75.1	79.4	76.9	77.1	77.9	80.1	78.9	79.7	80.0	79.6	-49 bps	-31 bps
Employee Expenses	1884.9	2074.9	2004.6	2037.1	2179.6	2402.0	2364.4	2363.3	2299.3	2454.6	2477.7	2552.3	2488.5	8.2	-2.5
% of Revenue	20.0	19.3	18.3	18.1	19.9	20.1	19.4	19.1	19.2	19.4	18.6	18.7	19.2	1 bps	54 bps
Other Expenditure	2681.9	2902.3	3283.1	3396.5	3671.6	3450.9	3827.5	3928.2	4211.6	3864.6	4308.6	4190.3	4408.3	4.7	5.2
% of Revenue	28.4	27.0	30.0	30.2	33.6	28.9	31.4	31.7	35.1	30.5	32.4	30.6	34.0	-113 bps	338 bps
Total Expenditure	7106.4	7877.4	7995.7	8237.3	8101.4	8611.1	8978.9	9028.4	8891.4	8994.7	9480.5	9483.1	9534.0	7.2	0.5
% of Revenue	75.2	73.2	73.0	73.3	74.1	72.1	73.6	72.9	74.2	71.1	71.3	69.3	73.6	-63 bps	423 bps
EBITDA	2340.4	2884.4	2956.6	3003.6	2829.3	3329.7	3213.5	3352.3	3091.5	3658.1	3810.9	4192.4	3424.9	10.8	-18.3
EBITDA Margin (%)	24.8	26.8	27.0	26.7	25.9	27.9	26.4	27.1	25.8	28.9	28.7	30.7	26.4	63 bps	-423 bps
Depreciation	556.5	588.0	610.0	660.0	671.5	651.3	632.8	622.1	650.4	655.1	625.9	630.6	663.8	2.1	5.3
Other Income	113.6	2.1	85.2	173.9	373.2	204.4	293.6	250.2	605.9	532.6	354.0	465.6	612.9	1.1	31.6
PBIT	1897.5	2298.5	2431.8	2517.5	2531.0	2882.9	2874.3	2980.3	3047.1	3535.5	3539.0	4027.4	3373.9	10.7	-16.2
Interest	37.3	13.7	19.4	46.2	92.7	80.9	49.3	34.7	73.6	61.5	69.2	51.5	49.1	-33.2	-4.6
Less: Exceptional Items	3935.8	0.0	0.0	0.0	171.4	322.9	0.0	69.8	101.6	0.0	0.0	316.2	361.7		
PBT	-2075.6	2284.8	2412.4	2471.3	2266.9	2479.1	2825.0	2875.8	2871.9	3474.0	3469.8	3659.8	2963.1	3.2	-19.0
Total Tax	146.8	189.0	152.3	283.4	222.9	468.1	390.1	432.3	148.9	552.3	567.2	558.9	1093.7	634.4	95.7
PAT before MI	-2222.4	2095.9	2260.2	2187.9	2044.0	2011.0	2434.9	2443.5	2723.0	2921.7	2902.6	3100.9	1869.4	-31.3	-39.7
Minority Interest	49.9	32.5	-6.3	14.7	-1.6	-16.9	9.6	36.8	4.2	24.9	-2.8	1.0	4.1	-2.6	321.9
PAT after MI	-2272.2	2063.3	2266.5	2173.1	2045.5	2027.9	2425.3	2406.7	2718.8	2896.8	2905.4	3099.9	1865.4	-31.4	-39.8
Profit from Associates	-5.0	-2.5	-4.3	-7.3	-33.8	-7.4	-15.7	-7.5	-7.9	-10.7	6.7	-4.6	-6.7		
PAT	-2277.3	2060.9	2262.2	2165.8	2111.7	2020.5	2409.6	2399.2	2711.0	2886.1	2912.1	3095.4	1858.6	-31.4	-40.0
Adjusted PAT	1582.1	2060.9	2262.2	2165.8	2166.3	2284.5	2375.5	2583.5	2750.8	2835.6	3040.2	3177.4	2390.0	-13.1	-24.8
Adjusted EPS (₹)	6.6	8.6	9.4	9.0	9.0	9.5	9.9	10.8	11.5	11.8	12.7	13.2	10.0		
Share Capital (cr)	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9		

Source: Company, ICICI Direct Research

## Q4FY25 Results / Conference call highlights

## India

- Sun Pharma has a market share of 8.3% in IPM. It has done better than IPM growth led by new product launches and volume growth.
- The company launched 10 new products in Q4FY25.
- Drugs for weight management and Diabetes management are in pipeline expected to be launched going ahead.

## US

- The growth for FY25 was led by Specialty portfolio which was offset by decline in generics.
- Sun launched 2 generic products in the US in Q4FY25
- Revlimid sales in Q4FY25 was similar to Q3FY25 not very significant. We continue to see pressure on pricing.


## Global Specialty

- Specialty business growth in FY25 was driven by Ilumya, Cequa, Winlevi, and Odomzo.
- Global Ilumya sales 17% up YoY to US\$681 in FY25, this doesn't include end market sales of the partner.
- Leqselvi could be launched in US in Q2FY26 which is delayed by 3 quarters. While the patent litigation is ongoing, the court has not restricted it from launching the product. In case the trial ruling comes against that of Sun, the launch may get delayed till patent expiry in December, 2026.
- The management is seeking a partner for the launch of MM-II in certain geographies.

## Others

- The management guided for a mid to high single digit revenue growth for FY26.
- The tax rate is expected to go upwards going ahead from the current levels.
- In Emerging Formulations segment Romania Brazil and Russia done well in local currencies.
- Sun is planning to spend US\$ 100 million for commercialisation of new specialty products mainly for promotion and addition of field force.

- R&D Spend for FY26 is expected to be around 6-8%
- The company's efforts for the remediation of the Mohali Plant are ongoing.
- Remediation at Sun's Halol Plant is completed and they have requested the USFDA for an inspection.

**Exhibit 2: 2-year forward PE band**

Source: Company, ICICI Direct Research

## Financial Tables

Exhibit 3: Profit and loss statement				
(Year-end March)	FY24	FY25	FY26E	₹ crore
Revenues	48,496.9	52,578.4	56,864.8	62,059.5
Growth (%)	10.5	8.4	8.2	9.1
Raw Material Expenses	10,662.6	10,747.4	12,225.9	13,342.8
Employee Expenses	9,429.1	9,973.1	11,088.6	12,101.6
Other Expenditure	15,418.2	16,771.8	17,628.1	19,238.4
Total Operating Expenditure	35,509.9	37,492.3	40,942.7	44,682.8
<b>EBITDA</b>	<b>12,987.0</b>	<b>15,086.2</b>	<b>15,922.1</b>	<b>17,376.7</b>
Growth (%)	11.2	16.2	5.5	9.1
Depreciation	2,556.6	2,575.4	2,678.5	2,781.5
Interest	238.5	231.4	201.9	172.5
Other Income	1,354.2	1,965.0	1,688.5	1,842.8
PBT	11,546.1	14,244.5	14,730.3	16,265.3
Less: Exceptional Items	494.3	677.9	0.0	0.0
Total Tax	1,439.5	2,772.0	2,798.7	3,415.7
PAT before MI	9,612.3	10,794.6	11,931.5	12,849.6
Minority Interest	33.7	27.1	0.0	0.0
PAT	9,540.3	10,752.2	11,904.7	12,822.8
<b>Adjusted PAT</b>	<b>9,994.4</b>	<b>11,443.2</b>	<b>11,904.7</b>	<b>12,822.8</b>
Growth (%)	15.5	14.5	4.0	7.7
<b>EPS (Adjusted)</b>	<b>41.7</b>	<b>47.7</b>	<b>49.6</b>	<b>53.5</b>

Source: Company, ICICI Direct Research

Exhibit 4: Cash flow statement				
(Year-end March)	FY24	FY25	FY26E	₹ crore
Profit/(Loss) after taxation	9518.5	13275.3	11904.7	12822.8
Depreciation	2556.6	2575.4	2678.5	2781.5
(Inc)/Dec in Current Assets	567.8	-1845.3	-2851.5	-2758.6
(Inc)/Dec in Current Liabilities	494.3	1521.8	1583.8	1426.9
Others	-1002.2	-1455.0	201.9	172.5
<b>CF from operation Activities</b>	<b>12135.0</b>	<b>14072.1</b>	<b>13517.4</b>	<b>14445.2</b>
Purchase of Fixed Assets	-2171.0	-2067.6	-2000.0	-2000.0
(Inc)/Dec in Investments	768.4	-4108.4	-4000.0	-4000.0
Others	712.9	869.8	-346.4	-370.6
<b>CF from Investing Activities</b>	<b>-689.6</b>	<b>-5306.2</b>	<b>-6346.4</b>	<b>-6370.6</b>
Inc / (Dec) in Loan Funds	-3686.4	-4064.7	-300.0	-300.0
Inc / (Dec) in Equity Capital	0.0	0.0	0.0	0.0
Dividend and dividend tax	-2900.7	-3617.3	-3358.6	-3358.6
Other Financial Activities	-123.1	-223.8	-201.9	-172.5
<b>CF from Financing Activities</b>	<b>-6710.2</b>	<b>-7905.8</b>	<b>-3860.5</b>	<b>-3831.1</b>
Cash generation during the year	4735.2	-2155.0	3310.4	4243.4
Op bal Cash & Cash equivalents	4623.1	9285.7	10268.8	13579.2
<b>Closing Cash/ Cash Equivalent</b>	<b>9358.4</b>	<b>7130.7</b>	<b>13579.2</b>	<b>17822.6</b>
<b>Free Cash Flow</b>	<b>9964.0</b>	<b>12004.5</b>	<b>11517.4</b>	<b>12445.2</b>

Source: Company, ICICI Direct Research

Exhibit 5: Balance Sheet				
(Year-end March)	FY24	FY25	FY26E	₹ crore
Equity Capital	239.9	239.9	239.9	239.9
Reserve and Surplus	63,426.8	71,978.1	80,524.2	89,988.3
Total Shareholders funds	63,666.8	72,218.0	80,764.1	90,228.3
Total Debt	3,272.3	2,359.7	2,059.7	1,759.7
Deferred Tax Liability	155.1	192.4	205.9	220.3
Minority Interest	3,439.2	267.9	267.9	267.9
Other LT Liabilities & LT Provision	915.2	872.2	933.3	998.6
<b>Total Liabilities</b>	<b>71,448.5</b>	<b>75,910.3</b>	<b>84,230.9</b>	<b>93,474.8</b>
Gross Block - Fixed Assets	35,868.3	37,478.1	38,978.1	40,478.1
Accumulated Depreciation	21,255.8	23,831.2	26,509.7	29,291.2
Net Block	14,612.4	13,646.9	12,468.4	11,186.9
Capital WIP	5,353.9	6,644.0	7,144.0	7,644.0
Total Fixed Assets	19,966.3	20,290.8	19,612.4	18,830.8
Investments	15,025.8	18,353.8	22,353.8	26,353.8
Deferred tax assets	4,103.7	4,407.6	4,716.1	5,046.2
Goodwill on Consolidation	8,599.0	8,939.4	8,939.4	8,939.4
LT Loans, Advances & Assets	2,877.8	1,140.6	1,220.5	1,305.9
Cash	9,285.7	10,268.8	13,579.2	17,822.6
Debtors	11,249.4	13,046.1	14,109.7	15,398.6
Loans and Advances	65.0	48.4	51.8	55.4
Inventory	9,868.3	10,243.3	11,652.6	12,717.0
Other current assets	4,422.1	5,361.8	5,737.1	6,138.7
Total Current Assets	34,890.4	38,968.4	45,130.3	52,132.3
Creditors	5,653.3	6,184.3	7,035.2	7,677.8
Provisions & other current liability	8,361.0	10,005.9	10,706.4	11,455.8
<b>Total Current Liabilities</b>	<b>14,014.3</b>	<b>16,190.3</b>	<b>17,741.5</b>	<b>19,133.6</b>
Net Current Assets	20,876.1	22,778.1	27,388.8	32,998.7
<b>Application of Funds</b>	<b>71,448.6</b>	<b>75,910.3</b>	<b>84,230.9</b>	<b>93,474.8</b>

Source: Company, ICICI Direct Research

Exhibit 6: Key ratios				
(Year-end March)	FY24	FY25	FY26E	FY27E
<b>Per share data (₹)</b>				
Adjusted EPS	41.7	47.7	49.6	53.5
BV per share	265.4	301.0	336.7	376.1
Dividend per share	13.5	14.0	14.0	14.0
Cash Per Share	38.7	42.8	56.6	74.3
<b>Operating Ratios (%)</b>				
Gross Margin	78.0	79.6	78.5	78.5
EBITDA Margin	26.8	28.7	28.0	28.0
PAT Margin	20.6	21.8	20.9	20.7
Inventory days	338	348	348	348
Debtor days	85	91	91	91
Creditor days	194	210	210	210
Asset Turnover	1.4	1.4	1.5	1.5
EBITDA Conversion rate	93.4	93.3	84.9	83.1
<b>Return Ratios (%)</b>				
RoE	15.7	15.8	14.7	14
RoCE	17.5	20.2	18.8	19
RoIC	23.6	30.6	30.7	32
<b>Valuation Ratios (x)</b>				
P/E	41.2	36.6	33.0	31
EV / EBITDA	29.2	24.6	23.0	21
EV / Net Sales	7.8	7.1	6.4	6
Market Cap / Sales	8.1	7.5	6.9	6
Price to Book Value	6.2	5.4	4.9	4
<b>Solvency Ratios</b>				
Debt / EBITDA	0.3	0.2	0.1	0
Debt / Equity	0.1	0.0	0.0	0
Current Ratio	1.8	1.8	1.8	2
Working Capital Cycle	229	228	228	228

Source: Company, ICICI Direct Research

## ANALYST CERTIFICATION

IWe, Siddhant Khandekar, Inter CA; Shubh Mehta, MBA(Tech); Vedant Nilekar, MBA; Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on [www.icicibank.com](http://www.icicibank.com).

**Investments in securities market are subject to market risks. Read all the related documents carefully before investing.**

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Anoop Goyal

Contact number: 022-40701000 E-mail Address: [complianceofficer@icicisecurities.com](mailto:complianceofficer@icicisecurities.com)

For any queries or grievances: Mr. Bhavesh Soni Email address: [headservicequality@icicidirect.com](mailto:headservicequality@icicidirect.com) Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit [icicidirect.com](http://icicidirect.com) to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.